



# Biomarkers in neurodegenerative disorders: translating research into clinical practice

Manuel Menéndez-González<sup>1,2,3\*</sup>

<sup>1</sup> Neurology Unit, Hospital Álvarez-Buylla, Oviedo, Spain

<sup>2</sup> Departamento de Morfología y Biología Celular, Universidad de Oviedo, Oviedo, Spain

<sup>3</sup> Instituto de Neurociencias, Universidad de Oviedo, Oviedo, Spain

\*Correspondence: [manuelmenendezgonzalez@gmail.com](mailto:manuelmenendezgonzalez@gmail.com)

## Edited and reviewed by:

Rodrigo Orlando Kuljiš, Zdrav Mozak Limitada, Chile

**Keywords:** biomarker, MTAi, neurodegenerative disease, Neurodegenerative Diseases, Parkinson's Disease, Huntington's Disease, Frontotemporal dementia (FTD), CSF biomarkers

When I was invited by Frontiers to serve as Guest Editor of a Research Topic I had no doubts about the topic to address: the clinical use of biomarkers for neurodegenerative disorders. The prevalence of ND is increasing dramatically and one of the major challenges today is the need of early and accurate diagnosis, the other is the need of more effective therapies -in turn the development of such therapies also requires early and accurate diagnosis-. The main hope for an earlier and more accurate diagnosis comes from the use of biomarkers. Much research is being done trying to solve the many interrogates related to the role of biomarkers in the early diagnosis, differential diagnosis, and follow-up of neurodegenerative disorders. This is a field where translational research is intense enough to make this topic interesting for basic researchers and clinicians. Indeed, the response to the call for contributions was very good. I had the opportunity to receive and edit a good amount of high quality articles devoted to diverse techniques across several ND from different perspectives.

Several articles are devoted to laboratory, biochemical biomarkers in neurodegenerative dementias. Researchers from Japan assessed the association of plasmatic annexin A5 with Alzheimer's disease and with Dementia with Lewy Bodies, and they found annexin A5 is indeed a good marker of both conditions (Sohma et al., 2013). Regarding the usefulness of CSF biomarkers in the differential diagnosis of FTLD vs. AD, an interesting review by D Irwin, J Trojanowski, and M Grossman highlight that CSF measurements of A $\beta$ 1-42, t-tau, and p-tau differ significantly in FTLD from the abnormal levels seen in AD, and in a subset of both FTLD-tau and FTLD-TDP there are extremely low levels of t-tau of unclear etiology (Irwin et al., 2013). In other review, J Moreth, C Mavoungou, and K Schindowski discuss the role of CSF A $\beta$  in ongoing clinical trials for AD as well as the latest regulatory strategies (Moreth et al., 2013). Researchers for the Alzheimer's Disease Neuroimaging Initiative (ADNI) evaluated the association of APOE with amyloid deposition, cerebrospinal fluid levels (CSF) of A $\beta$ , tau, and p-tau, brain atrophy, cognition, and cognitive complaints in patients with early-Mild Cognitive Impairment (E-MCI) and cognitively healthy older adults (HC) and found that cortical amyloid deposition and CSF levels of A $\beta$  were significantly associated with APOE  $\epsilon$ 4 status but not E-MCI diagnosis, with  $\epsilon$ 4 positive participants showing more amyloid deposition and lower levels of CSF A $\beta$  than  $\epsilon$ 4 negative

participants (Risacher et al., 2013). These findings have practical repercussion, since clinicians, and researchers should consider APOE genotyping when evaluating biomarkers in early stages of the disease.

A number of articles addressed neuroimaging techniques. Researchers from Karolinska Institute and King's College London explored how the progression of atrophy in dementia may be predicted on the basis of the anatomical connectivity of the first atrophic region and found that the subcallosal medial prefrontal cortex is atrophied (in different extent depending on the brain hemisphere assessed) in FTD, SD, PNFA and AD (Lindberg et al., 2012). These results should also be taken into account when using neuroimaging biomarkers in the differential diagnosis of neurodegenerative dementias. There are two neuroimaging methods reports. One proposes the use of viscous fluid registration in voxel based morphometry studies to enhance sensitivity and localizing power in the software package SPM (Pereira et al., 2013) and the other describes the Medial Temporal Atrophy index (MTAi), a simple planimetric method for measuring the relative extent of atrophy of the Medial Temporal Lobe (MTA) in relation to the global brain atrophy (Menéndez-González et al., 2014a). Following with simple methods for assessing MTA in the clinical setting, researchers from Florida describe the utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI, and cognitively normal elderly subjects (Duara et al., 2013).

Some other studies followed a multidimensional approach. In a multicentric study researchers performed a longitudinal and multidimensional assessment of individuals with the gene expansion for Huntington disease (HD) but not yet diagnosed who were evaluated annually. They identified three clusters that represented primarily cognitively impaired, behaviorally impaired, and cognitively preserved phenotypes. Thus, this multidimensional method results in an earlier diagnosis with less motor and cognitive impairment than a motor diagnosis. These findings have implications for designing preventive trials and providing clinical care in prodromal HD (Biglan et al., 2013). Again researchers for the ADNI, show how the short-term (1 year) prognosis of progression from amnesic MCI to dementia relates strongly to baseline markers of neurodegeneration, with the AD signature MRI biomarker of cortical thickness performing the best among MRI and CSF

markers studied here. However, longer-term (3 year) prognosis in these individuals was better predicted by a marker indicative of brain amyloid. Prediction of time-to-event in a survival model was predicted by the combination of these biomarkers. These results provide further support for emerging models of the temporal relationship of pathophysiologic events in AD and demonstrate the utility of these biomarkers at the prodromal stage of the illness (Dickerson and Wolk, 2013). Gómez-Ramírez and Wu review the network-based approach in biomarker discovery as a source of key insights to fully understand the network degeneration hypothesis (the disease starts in specific network areas and progressively spreads to connected areas of the initial loci-networks, a concept also addressed in the article by Lindberg et cols.) and introduce a new framework for the quantitative study of biomarkers that can help shorten the transition between academic research and clinical diagnosis in AD (Gómez-Ramírez and Wu, 2014).

We also have two original reports on Parkinson's disease (PD) and parkinsonisms. One is on the use of DaTSPECT in the diagnosis of patients with hard-to-classify tremor who have a normal DaT-SPECT. Researchers from Spain and Mexico make a clinical follow up study and provide a list of the final diagnosis behind these cases (Menéndez-González et al., 2014b) at the time of discussing the role of DaTSPECT in the diagnosis of patients with tremor. In the other report, a group of researchers led by Prof Parnetti, assesses the differential role of CSF alpha-synuclein species, tau, and A $\beta$ 42 in PD and conclude that the combination of CSF o/t- $\alpha$ -syn and A $\beta$ 42/tau ratios improve the diagnostic accuracy of PD and that PD patients showing low CSF A $\beta$ 42 levels at baseline are more prone to develop cognitive decline (Parnetti et al., 2014).

Finally, I also had the opportunity of publishing a couple of opinion articles: one on the many questions arising about the use of biomarkers for diagnosing neurodegenerative diseases routinely (Menéndez-González, 2014a) and other discussing the safety issues related to lumbar punctures performed for CSF analysis for the diagnosis of AD in daily clinical practice (Menéndez-González, 2014b).

Research on biomarkers on neurodegenerative disorders is a hot topic where much work has to be done yet. As we can learn from this Research Topic, biomarkers are allowing us to expand the knowledge on the biological and anatomical basis of neurodegenerative diseases and to implement diagnostic techniques in clinical practice and clinical trials.

## REFERENCES

Biglan, K. M., Zhang, Y., Long, J. D., Geschwind, M., Kang, G. A., Killoran, A., et al. (2013). Refining the diagnosis of Huntington disease: the PREDICT-HD study. *Front. Aging Neurosci.* 5:12. doi: 10.3389/fnagi.2013.00012

Dickerson, B. C., and Wolk, D. A. (2013). Biomarker-based prediction of progression in MCI: comparison of AD signature and hippocampal volume with spinal fluid amyloid- $\beta$  and tau. *Front. Aging Neurosci.* 5:55. doi: 10.3389/fnagi.2013.00055

Duara, R., Loewenstein, D. A., Shen, Q., Barker, W., Varon, D., Greig, M. T., et al. (2013). The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI and cognitively normal elderly subjects. *Front. Aging Neurosci.* 5:47. doi: 10.3389/fnagi.2013.00047

Gómez-Ramírez, J., and Wu, J. (2014). Network-based biomarkers in Alzheimer's disease: review and future directions. *Front. Aging Neurosci.* 6:12. doi: 10.3389/fnagi.2014.00012

Irwin, D. J., Trojanowski, J. Q., and Grossman, M. (2013). Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. *Front. Aging Neurosci.* 5:6. doi: 10.3389/fnagi.2013.00006

Lindberg, O., Westman, E., Karlsson, S., Östberg, P., Svensson, L. A., Simmons, A., et al. (2012). Is the subcallosal medial prefrontal cortex a common site of atrophy in Alzheimer's disease and frontotemporal lobar degeneration? *Front. Aging Neurosci.* 4:32. doi: 10.3389/fnagi.2012.00032

Menéndez-González, M. (2014a). The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice. *Front. Aging Neurosci.* 6:45. doi: 10.3389/fnagi.2014.00045

Menéndez-González, M. (2014b). Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe? *Front. Aging Neurosci.* 6:65. doi: 10.3389/fnagi.2014.00065

Menéndez-González, M., López-Muñoz, A., Vega, J. A., Salas-Pacheco, J. M., and Arias-Carrión, O. (2014a). MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging. *Front. Aging Neurosci.* 6:23. doi: 10.3389/fnagi.2014.00023

Menéndez-González, M., Tavares, F., Zeidan, N., Salas-Pacheco, J. M., and Arias-Carrión, O. (2014b). Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study. *Front. Aging Neurosci.* 6:56. doi: 10.3389/fnagi.2014.00056

Moreth, J., Mavoungou, C., and Schindowski, K. (2013). Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. *Front. Aging Neurosci.* 5:25. doi: 10.3389/fnagi.2013.00025

Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., et al. (2014). Differential role of CSF alpha-synuclein species, tau, and A $\beta$ 42 in Parkinson's disease. *Front. Aging Neurosci.* 6:53. doi: 10.3389/fnagi.2014.00053

Pereira, J. M. S., Acosta-Cabronero, J., Pengas, G., Xiong, L., Nestor, P. J., and Williams, G. B. (2013). VBM with viscous fluid registration of gray matter segments in SPM. *Front. Aging Neurosci.* 5:30. doi: 10.3389/fnagi.2013.00030

Risacher, S. L., Kim, S., Shen, L., Nho, K., Foroud, T., Green, R. C., et al. (2013). The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). *Front. Aging Neurosci.* 5:11. doi: 10.3389/fnagi.2013.00011

Sohma, H., Imai, S.-I., Takei, N., Honda, H., Matsumoto, K., Utsumi, K., et al. (2013). Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies. *Front. Aging Neurosci.* 5:15. doi: 10.3389/fnagi.2013.00015

**Conflict of Interest Statement:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 13 August 2014; accepted: 25 September 2014; published online: 21 October 2014.

Citation: Menéndez-González M (2014) Biomarkers in neurodegenerative disorders: translating research into clinical practice. *Front. Aging Neurosci.* 6:281. doi: 10.3389/fnagi.2014.00281

This article was submitted to the journal *Frontiers in Aging Neuroscience*.

Copyright © 2014 Menéndez-González. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.